Article
A novel approach to detect resistance mechanisms reveals FGR as a factor mediating HDAC inhibitor SAHA resistance in B-cell lymphoma.
Molecular oncology - 1 Oct 2016
Joosten Maria, Ginzel Sebastian, Blex Christian, Schmidt Dmitri, Gombert Michael, Chen Cai, Linka René Martin, Gräbner Olivia, Hain Anika, Hirsch Burkhard, Sommerfeld Anke, Seegebarth Anke, Gruber Uschi, Maneck Corinna, Zhang Langhui, Stenin Katharina, Dieks Henrik, Sefkow Michael, Münk Carsten, Baldus Claudia D, Thiele Ralf, Borkhardt Arndt, Hummel Michael, Köster Hubert, Fischer Ute, Dreger Mathias, Seitz Volkhard
Abstract excerpt
Histone deacetylase (HDAC) inhibitors such as suberoylanilide hydroxamic acid (SAHA) are not commonly used in clinical practice for treatment of B-cell lymphomas, although a subset of patients with refractory or relapsed B-cell lymphoma achieved partial or complete remissions. Therefore, the purpose of this study was to identify molecular features that predict the response of B-cell lymphomas to SAHA treatment....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.